PRA Health Sciences, Inc. (PRAH) Receives $88.09 Consensus Price Target from Brokerages

Shares of PRA Health Sciences, Inc. (NASDAQ:PRAH) have been assigned an average rating of “Buy” from the twelve ratings firms that are presently covering the stock, Marketbeat reports. One research analyst has rated the stock with a hold recommendation and eleven have given a buy recommendation to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $88.09.

A number of research analysts recently issued reports on PRAH shares. SunTrust Banks, Inc. reissued a “buy” rating on shares of PRA Health Sciences in a research note on Wednesday, August 9th. Credit Suisse Group boosted their target price on shares of PRA Health Sciences from $80.00 to $84.00 and gave the stock an “outperform” rating in a research note on Tuesday, August 8th. Robert W. Baird boosted their target price on shares of PRA Health Sciences from $82.00 to $83.00 and gave the stock an “outperform” rating in a research note on Tuesday, August 8th. Citigroup Inc. reaffirmed a “buy” rating and set a $93.00 target price (up previously from $90.00) on shares of PRA Health Sciences in a research note on Thursday, August 10th. Finally, Jefferies Group LLC reissued a “buy” rating and issued a $92.00 price objective (up previously from $88.00) on shares of PRA Health Sciences in a research note on Thursday, August 10th.

COPYRIGHT VIOLATION WARNING: “PRA Health Sciences, Inc. (PRAH) Receives $88.09 Consensus Price Target from Brokerages” was posted by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this piece on another publication, it was copied illegally and republished in violation of United States and international copyright & trademark legislation. The legal version of this piece can be viewed at https://stocknewstimes.com/2017/11/17/pra-health-sciences-inc-prah-receives-88-09-consensus-price-target-from-brokerages.html.

Shares of PRA Health Sciences (NASDAQ:PRAH) traded up $1.49 during mid-day trading on Monday, reaching $79.90. 320,826 shares of the company’s stock traded hands, compared to its average volume of 534,144. The company has a debt-to-equity ratio of 1.38, a current ratio of 1.01 and a quick ratio of 1.01. The firm has a market capitalization of $4,970.00 and a P/E ratio of 28.89. PRA Health Sciences has a 1 year low of $51.16 and a 1 year high of $84.38.

PRA Health Sciences (NASDAQ:PRAH) last issued its quarterly earnings data on Wednesday, October 25th. The medical research company reported $0.88 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.85 by $0.03. PRA Health Sciences had a net margin of 5.64% and a return on equity of 21.66%. The firm had revenue of $494.55 million during the quarter, compared to the consensus estimate of $477.89 million. During the same period last year, the business posted $0.64 earnings per share. The business’s revenue for the quarter was up 23.7% compared to the same quarter last year. research analysts forecast that PRA Health Sciences will post 3.2 earnings per share for the current fiscal year.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Teachers Advisors LLC raised its position in shares of PRA Health Sciences by 2.6% during the 1st quarter. Teachers Advisors LLC now owns 251,007 shares of the medical research company’s stock valued at $16,373,000 after buying an additional 6,402 shares in the last quarter. Legal & General Group Plc raised its position in shares of PRA Health Sciences by 7.1% during the 1st quarter. Legal & General Group Plc now owns 9,943 shares of the medical research company’s stock valued at $649,000 after buying an additional 663 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in shares of PRA Health Sciences by 61.8% during the 1st quarter. Dimensional Fund Advisors LP now owns 295,974 shares of the medical research company’s stock valued at $19,306,000 after purchasing an additional 113,074 shares during the last quarter. BlackRock Inc. grew its holdings in shares of PRA Health Sciences by 43,947.8% during the 1st quarter. BlackRock Inc. now owns 2,857,381 shares of the medical research company’s stock valued at $186,387,000 after purchasing an additional 2,850,894 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. grew its holdings in shares of PRA Health Sciences by 56.8% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 212,627 shares of the medical research company’s stock valued at $13,870,000 after purchasing an additional 77,057 shares during the last quarter. Institutional investors and hedge funds own 97.60% of the company’s stock.

About PRA Health Sciences

PRA Health Sciences, Inc is a contract research organization. The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases.

Analyst Recommendations for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Ratings for PRA Health Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply